Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Shares Outstanding (Weighted Average) (2020 - 2025)

Ovid Therapeutics' Shares Outstanding (Weighted Average) history spans 6 years, with the latest figure at $1171.0 for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 6.32% year-over-year to $1171.0; the TTM value through Dec 2025 reached $1171.0, down 6.32%, while the annual FY2025 figure was $1171.0, 6.32% down from the prior year.
  • Shares Outstanding (Weighted Average) reached $1171.0 in Q4 2025 per OVID's latest filing, down from $1250.0 in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $71.1 million in Q2 2025 to a low of $1171.0 in Q4 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $55.8 million, with a median of $70.4 million recorded in 2022.
  • The largest YoY upside for Shares Outstanding (Weighted Average) was 5686119.76% in 2025 against a maximum downside of 100.0% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $67.5 million in 2021, then grew by 4.36% to $70.4 million in 2022, then rose by 0.22% to $70.6 million in 2023, then plummeted by 100.0% to $1250.0 in 2024, then decreased by 6.32% to $1171.0 in 2025.
  • Per Business Quant, the three most recent readings for OVID's Shares Outstanding (Weighted Average) are $1171.0 (Q4 2025), $1250.0 (Q3 2025), and $71.1 million (Q2 2025).